








Day 1: 7 July 2023

Time	Programme	Speaker
0730 – 0815	Registration + Breakfast	
0815 – 0845	Integration of Currently Available Immunotherapies into Clinical Practice of Resectable NSCLC in Singapore 	Chair : Dr Yvonne Ang Speakers : Dr Ross Soo Dr Daniel Chan Dr Harish Mithiran Dr Ong Boon Hean
0845 – 0850	Welcome Address by President of the Singapore Society of Oncology	Dr Elaine Lim
0850 – 0900	Opening Address by Organising Chairs of SSO-ASM	Dr Raghav Sundar
	Head and Neck Track	Track Chairs : Dr Chong Wan Qin, Dr Teo Hui Lin
0900 – 0915	Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-gemcitabine Versus Cisplatin-fluorouracil Chemotherapy for N2-3 Nasopharyngeal Carcinoma: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial	Dr Melvin Chua
0915 – 0930	Primary Results of the Phase III KEYNOTE-412 Study: Pembrolizumab (Pembro) with Chemoradiation Therapy (CRT) VS Placebo Plus CRT for Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)	Dr Low Jia Li
0930 – 0945	Neoadjuvant Nivolumab, Paclitaxel and Carboplatin Followed by Response-Stratified Chemoradiation in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC): The DEPEND Trial	Dr Tan Teng Hwee
0945 – 1000	PD-1 Blockade with Sintilimab Plus Induction Chemotherapy and Concurrent Chemoradiotherapy (IC-CCRT) Versus IC-CCRT in Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC): A Multicenter Phase 3, Randomized Controlled Trial (CONTINUUM)	Dr Tan Chee Seng
1000 – 1015	Q&A	
1015 – 1030	Morning Tea	
	Survivorship Track	Track Chairs : Dr Rachel Wong, Dr Grace Yang
1030 – 1045	TCM in Oncology	Mr Ricky Ang
1045 – 1100	Use of Acupuncture in Cancer-Related Symptoms	Ms Sheryl Tay
1100 – 1115	Nutritional Considerations for Oncology Patients	Ms Sow Bao Yin
1115 – 1125	Q&A	

1125 – 1155	Breakthroughs in Early Lung Cancer		Chair : Dr Yvonne Ang Speaker : Prof Tom John
1155 – 1210	A Spotlight on EGFR Exon 20 Insertion Mutations – A Target not to be Missed.		Assoc Prof Daniel Tan
1210 – 1225	Advancing the Treatment Landscape for Lung Cancer with KRAS Targets		Prof Sanjay Popat
1225 – 1315	Lunch + Exhibition Break		
	Lung Track		Track Chairs : Dr Yvonne Ang, Dr Gillianne Lai
1315 – 1330	CCTG IND.227: A Randomized Phase 3 Study of Chemotherapy versus Chemotherapy plus Pembrolizumab in Treatment-Naïve Pleural Mesothelioma		Dr Tan Wei Chong
1330 – 1345	KEYNOTE-789 – Pemetrexed and Platinum With or Without Pembrolizumab for TKI Resistant EGFR-Mutant Nonsquamous NSCLC		Dr Amit Jain
1345 – 1400	Keynote 671 (Randomized, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Platinum-Based Chemotherapy Followed by Resection and Pembrolizumab or Placebo for Early-Stage NSCLC)		Dr Low Jia Li
1400 - 1415	Overall Survival Analysis from the ADAURA Trial of Adjuvant Osimertinib in Patients with Resected EGFR-Mutated Stage IB-IIIa NSCLC		Dr Stephanie Saw
1415 – 1430	Q&A		
1430 – 1500	Evolving Standard of Care in First-Line DLBCL		Chair: Dr Lee Yuh Shan Speaker: Dr Raymond Wong
	Haematology Track		Track Chairs : Dr Tan Ya Hwee, Dr Lawrence Ng
1500 – 1515	T-cell Redirecting Therapies for Multiple Myeloma		Dr Chen Yunxin
1515 – 1530	MDS/Leukemia		Dr Nurul Aidah
1530 – 1545	Advanced-Stage Classical Hodgkin Lymphoma: SWOG S1826 trial - Do We Have a New Standard of Care?		Dr Lee Yuh Shan
1545 – 1600	TRIANGLE Study – Autologous Transplantation after Rituixmab/Ibrutinib/Ara-C Containing Induction in Generalized Mantle Cell Lymphoma – A Randomized European MCL Network Trial		Dr Joanne Lee

1600 – 1615	Q&A	
1615 – 1645	<p>A PROfound Discussion: Bringing Clinical Evidence to Life Patient Case Sharing: Case Sharing and Outcomes with Targeted Therapy</p> 	<p>Speakers : Dr Robert Walsh Dr Akhil Chopra</p>
	Genitourinary Track	<p>Track Chairs : Dr Johan Chan, Dr Robert Walsh</p>
1645 – 1700	<p>Efficacy and Safety of Atezolizumab Plus Cabozantinib VS Cabozantinib Alone after Progression with Prior Immune Checkpoint Inhibitor (ICI) Treatment in Metastatic Renal Cell Carcinoma (RCC): Primary PFS Analysis from the Phase 3, Randomized, Open-label CONTACT-03 Study.</p> 	<p>Dr Tanujaa Rajasekaran</p>
1700 – 1715	<p>TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide (ENZA) Versus Placebo + ENZA as First Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations</p>	<p>Dr Akhil Chopra</p>
1715 – 1730	<p>Phase 3 THOR study: Results of Erdafitinib (erda) Versus Chemotherapy (chemo) in Patients (pts) with Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Receptor Alterations (FGFRalt).</p>	<p>Dr Natalie Ngoi</p>
1730 – 1740	Q&A	
End		